Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DARA

(DARA) (DARA) Stock Price, News & Analysis

(DARA) logo

About (DARA) Stock (NASDAQ:DARA)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.32
$0.33
52-Week Range
N/A
Volume
13,850 shs
Average Volume
118,843 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company's primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

Remove Ads
Receive DARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (DARA) and its competitors with MarketBeat's FREE daily newsletter.

DARA Stock News Headlines

What to do with your collapsing portfolio…
There might be only one way to save your retirement in this volatile time. After watching investors lose $6 trillion in market cap in a matter of DAYS... And after seeing businesses bleeding dry as trade tensions spiral out of control... What the acclaimed “Market Wizard” Larry Benedict — who beat the market by 103% during the 2008 crash — is about to reveal could not only save your retirement from Trump's tariffs…
See More Headlines

DARA Stock Analysis - Frequently Asked Questions

(DARA) (NASDAQ:DARA) released its earnings results on Monday, November, 2nd. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, hitting analysts' consensus estimates of ($0.14). The specialty pharmaceutical company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $0.83 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that (DARA) investors own include Castleton Technology (CTP), Richland Resources Ltd (RLD.L) (RLD), Thor Energy (THR), Global Invacom Group (GINV), Legendary Investments (LEG), iPass (IPAS) and Aeterna Zentaris (AEZS).

Company Calendar

Last Earnings
11/02/2015
Today
4/16/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:DARA
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:DARA) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners